

## Course 6 References: Prescribing an Opioid

1. Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: Tailoring therapy to meet patient needs. *Mayo Clin Proc.* Jul 2009; 84(7): 602–612.
2. Atkinson TJ, Fudin J, Pandula A, Mirza M. Medication pain management in the elderly: unique and underutilized analgesic treatment options. *Clin Ther.* 2013;35:1669-1689.
3. Black F, Downing GM. *Pain, analgesics.* In: Downing GM, Wainwright W, eds. *Medical Care of the Dying.* 4<sup>th</sup> ed. Victoria, Canada: Victoria Hospice Society; 2006.
4. Bruera E, de Stoutz ND, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. *J Pain Symptom Manage.* 1995;10(5):378-384.
5. Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. Canada: National Opioid Use Guideline Group (NOUGG). <http://nationalpaincentre.mcmaster.ca/opioid/>. Published April 2010. Accessed December 15, 2014.
6. Chappell D, Rehm M, Conzen P. Methylnaltrexone for opioid- induced constipation in advanced illness. *N Engl J Med.* 2008;359:1071.
7. Chou R et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain.* Feb 2009;10(2):113-130.
8. Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. *J Pain.* 2009;10:131-146
9. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. *Clin Ther.* Aug 2001;23(8):1296-310.
10. Davis M, Parala-Metz A. Cancer pain. Cleveland Clinic Center for Continuing Education website. <http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/cancer-pain/#top>. Published September 2013. Accessed December 15, 2014.

11. Ezenwa MO, Ameringer S, Ward SE, Serlin RC. Racial and ethnic disparities in pain management in the United States. *J Nurs Scholarsh*. 2006;38:225-233.
12. Extended-Release (ER) and Long-Acting (LA) opioid analgesics risk evaluation and mitigation strategy (REMS). U.S. Food and Drug Administration website. <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafety/InformationforPatientsandProviders/UCM311290.pdf>. Published July 2012. Updated October 2013. Accessed June 2, 2014.
13. FDA recommends health care professionals discontinue prescribing and dispensing prescription combination drug products with more than 325 mg of acetaminophen to protect consumers. U.S. Food and Drug Administration website. <http://www.fda.gov/Drugs/DrugSafety/ucm381644.htm>. Published January 1, 2014. Accessed June 2, 2014.
14. Fine PG, Portney RK and the Ad Hoc Expert Panel on Evidence review and guidelines for opioid rotation. Establishing “best practice” for opioid rotation: Conclusions of an expert panel. *J Pain Symptom Manage*. 2009; 38: 418-425.
15. Gallagher R. Killing the symptom without killing the patient. *Can Fam Physician*. Jun 2010; 56(6): 544–546.
16. Gartner R, Jensen MB, Nielsen J, Ewertz M, et al. Prevalence of and factors associated with persistent pain following breast cancer surgery. *JAMA*. 2009; 302(18): 1985-1992.
17. Gerald FG, Robert FS, eds. *Encyclopedia of pain*, 2nd ed. Springer Berlin Heidelberg; 2013. DOI: 1007/978-3-642-28753-4\_200732.
18. Harlos M. Symptom management in comfort end-of-life care of pneumonia. <http://palliative.info>. Accessed December 15, 2014.
19. Health Care Association of New Jersey (HCANJ). Pain management guideline. Hamilton, NJ: Health Care Association of New Jersey (HCANJ). <http://www.guideline.gov/content.aspx?id=9744>. Published July 18, 2006. Accessed December 15, 2014.
20. Joint Commission. Safe use of opioids in hospitals. *Sentinel Event Alert*. 2012; 49:1-5.
21. Jongen JLM, Huijsman ML, Jessurun J, et al. The evidence for pharmacologic treatment of neuropathic cancer pain: Beneficial and adverse effects. *J Pain Symptom Manage*. Oct 2013;46(4):581-590.e1.
22. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. *Oncologist*. 2004;9(5):571-91.

23. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. *J Pain*. 2003;4:231-256.
24. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain (Review). The Cochrane Collaboration. [http://summaries.cochrane.org/CD006146/SYMPT\\_opioids-for-neuropathic-pain](http://summaries.cochrane.org/CD006146/SYMPT_opioids-for-neuropathic-pain). Published August 29, 2013. Accessed July 23, 2014.
25. Medical Subject Headings (MeSH). Bethesda, MD: National Center for Biotechnology Information. <http://www.ncbi.nlm.nih.gov/mesh>. Accessed April 1, 2014.
26. Mercadante S. Intravenous morphine for management of cancer pain. *Lancet Oncol*. 2010;11:484-489.
27. Mercadante S. Pharmacotherapy for breakthrough cancer pain. *Drugs*. 2012;72:181-190.
28. Merriam Webster Dictionary. <http://www.merriam-webster.com/>. Accessed June 2, 2014.
29. National Comprehensive Cancer Network(NCCN). Clinical Practice Guidelines in Oncology: Adult Cancer Pain: Version 1. 2014. <http://oralcancerfoundation.org/treatment/pdf/pain.pdf>. Published February 24, 2014. Accessed December 15, 2014.
30. Paice JA and Ferrell B. The management of cancer pain. *Cancer J Clin*. 2011; 61(3): 157-182.
31. Pain management: Pathophysiology of pain and pain assessment. AMA Online Learning Center. <https://cme.ama-assn.org/Activity/1196205/Detail.aspx>. Published June 30, 2013. Accessed June 2, 2014.
32. Pathan H, Williams J. Basic opioid pharmacology: an update. *Br J Pain*. 2012; 6(1), 11-16. DOI: 10.1177/2049463712438493.
33. Patient information: Side effects from medicines (The Basics). UpToDate website. [http://www.uptodate.com/contents/side-effects-from-medicines-the-basics?source=search\\_result&search=side+effects&selectedTitle=1~150](http://www.uptodate.com/contents/side-effects-from-medicines-the-basics?source=search_result&search=side+effects&selectedTitle=1~150). Accessed December 15, 2014.
34. Pasero C, McCaffery M. *Pain Assessment and Pharmacologic Management*. St Louis, MO: Mosby; 2011.
35. Practitioner's Manual: An Informational Outline of the Controlled Substances Act. U.S. Department of Justice Drug Enforcement Administration website. [http://www.deadiversion.usdoj.gov/pubs/manuals/pract/pract\\_manual012508.pdf](http://www.deadiversion.usdoj.gov/pubs/manuals/pract/pract_manual012508.pdf). Published 2006. Accessed June 30, 2014.

36. Purdue Pharma LP. Package insert: OxyContin.  
<http://www.pharma.com/PI/Prescription/Oxycontin.pdf>. Updated April 2014. Accessed December 15, 2014.
37. Sloan P. Review of oral oxymorphone in the management of pain. *Ther Clin Risk Manag*. 2008;4:777-787.
38. Smith HS. *Opioid Therapy in the 21st Century*. New York: Oxford University Press; 2013.
39. Smith HS. Rapid onset opioids in palliative medicine. *Ann Palliat Med*. 2012;1(1):45-52. DOI: 10.3978/j.issn.2224-5820.2012.01.01.
40. Smith HS, Smith JM, Seidner P. Opioid induced nausea and vomiting. *Ann Palliat Med*. 2012;1(2):121- 129. DOI: 10.3978/j.issn.2224-5820.2012.07.08.
41. Stolerman IP, ed. *Encyclopedia of psychopharmacology*. Springer Berlin Heidelberg; 2010. DOI: 1007/978-3-540-68706-1.
42. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med*. 2010;363:733-742.
43. Thomas JR, von Gunten CF. Pain in terminally ill patients: Guidelines for pharmacological management. *CNS Drugs*. 2003; 17(9), 621-631.
44. Tielemans MM, Eikendal T, Jansen JB, et al. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. *Drug Saf*. 2010;33:443-453.
45. Tramadol. Drug Enforcement Administration website.  
[http://www.deadiversion.usdoj.gov/drug\\_chem\\_info/tramadol.pdf](http://www.deadiversion.usdoj.gov/drug_chem_info/tramadol.pdf). Published July 2014. Accessed July 29, 2014.
46. Transmucol immediate release fentanyl (TIRF) risk evaluation and mitigation strategy (REMS). U.S. Food and Drug Administration website.  
<http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM289730.pdf>. Published December 2011. Updated November 2013. Accessed June 2, 2014.
47. Vargas-Schaffer G. Is the WHO analgesic ladder still valid? *Can Fam Physician*. 2010; 56(6): 514–517.

48. Waldman SA. Does potency predict clinical efficacy? Illustration through an antihistamine model. *Ann Allergy Asthma Immunol.* Jul 2002; 89(1):7-11.
49. Ware LJ, Epps CD, Herr K, Packard A. Evaluation of the Revised Faces Pain Scale, Verbal Descriptor Scale, Numeric Rating Scale, and Iowa Pain Thermometer in older minority adults. *Pain Manag Nurs.* 2006; 7:117-125.
50. WHO's cancer pain ladder for adults. World Health Organization website. <http://www.who.int/cancer/palliative/painladder/en/>. Accessed June 2, 2014.
51. Yoong J, Traeger LN, Gallagher ER, et al. A pilot study to investigate adherence to long-acting opioids among patients with advanced lung cancer. *J Palliat Med.* 2013;16(4): 391-396. DOI:10.1089/jpm.2012.0400.
52. Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. *Cochrane Database Syst Rev.* 2013;10.